|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present article describes the effect on glucose of small doses of subcutaneous glucagon to revert hypoglycemia and prevent severe events in small children with type 1 diabetes using a continuous glucose monitoring.
|
31673895 |
2020 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are emerging as an important therapy to consider for patients with type 2 diabetes (T2D) given this class of treatment's ability to reduce glycated haemoglobin and their associated weight loss and low risk for hypoglycaemia.
|
31801807 |
2020 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, given that studies with incretin receptor antagonists indicate that not all of the glucose-lowering effects of DPP-4 inhibition can be accounted for by GLP-1 alone, evidence supports the notion that GIP may play a role in mediating the anti-hyperglycaemic effects of DPP-4 inhibition, while its glucagonotropic actions at lower glucose levels may contribute to the low risk of hypoglycaemia associated with DPP-4 inhibitors.
|
31706956 |
2020 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A CGM-guided closed-loop rescue system can detect imminent hypoglycemia and deliver glucagon, reducing severe hypoglycemia in PBH.
|
31714583 |
2020 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucose transporter 2 (<i>Glut2</i>)-positive cells are sparsely distributed in brain and play an important role in the stimulation of glucagon secretion in response to hypoglycemia.
|
29561214 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detectable insulin at the time of hypoglycemia was measured in 17 of 20 infants while the same number (17/20) of infants had a positive glucagon stimulation test (GST).
|
31465295 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide an alternative to prandial insulin, with the benefits of fewer daily injections, and a lower risk of hypoglycemia and weight gain.
|
30610613 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Affected patients have larger systemic appearance of ingested glucose and greater postmeal secretion of insulin and GLP-1 compared to those with history of RYGB without symptomatic hypoglycemia.
|
31082828 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Pilot studies were reported in the fields of acute stroke, cardiac resuscitation, coronary care, and perioperative care that showed advantages for GLP-1 therapy, with normalisation of glucose, lower glucose variability, and lower risk of hypoglycaemia.
|
31141838 |
2019 |
|
Hypoglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Based on this model, we design infusion rates of either insulin (monotherapy) or insulin and glucagon (dual therapy) that can optimally maintain the blood glucose level within desired limits after consumption of a meal and prevent the onset of both hypoglycemia and hyperglycemia.
|
30893335 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients who have detectable C-peptide and/or are overweight or cannot achieve glycemic goals without hypoglycemia have been found to benefit the most from GLP-1 RA therapy.
|
31612934 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The glucose fall during cycling was diminished by a pre-exercise injection of 200 μg glucagon; however, no significant difference was seen in the number of events of hypoglycaemia.
|
30643924 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This work is the first demonstration of a glucose-responsive glucagon-delivery MN patch for the prevention of hypoglycemia, which has a tremendous potential to reduce the dangers of intensive insulin therapy and improve the quality of life of patients with diabetes and their caregivers.
|
31165524 |
2019 |
|
Hypoglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These findings define a novel mechanism for glucose regulation of glucagon release that underlies recovery from hypoglycaemia and may be disturbed in diabetes.
|
30953108 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetes increases the severity of impairment in PD, and GLP-1 improve it through its direct neuronal effect in addition to its indirect effect through producing hypoglycemia.
|
31654678 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.
|
31176298 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stimulation of epinephrine and glucagon release in response to hypoglycemia or glucopenia was diminished in both POMC- and MC4R-deficient mice, relative to their littermate controls.
|
30503832 |
2019 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon-like peptide-1 (GLP-1) receptor agonists are highly potent antihyperglycemic drugs that impose low risk of hypoglycemia and also result in body weight reduction.
|
30499733 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 (GLP-1) receptor agonists are appealing as glucose-lowering therapy for individuals with type 2 diabetes mellitus (T2DM) as they also reduce body weight and are associated with low rates of hypoglycaemia.
|
30362224 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk.
|
31275246 |
2019 |
|
Hypoglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Determining the different detection mechanisms, the phenotype of neurosecretion, and neural connections involving glucose-sensitive neurons is essential to understanding the response to hypoglycemia through modulation of food intake, thermogenesis, and activation of sympathetic and parasympathetic branches, inducing glucagon and epinephrine secretion and other hypothalamic-pituitary axis-dependent counterregulatory hormones, such as glucocorticoids and growth hormone.
|
29796992 |
2019 |
|
Hypoglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Glucagon plays critical role in glucose homoeostasis and increases blood glucose level during hypoglycaemia.
|
29756500 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
During the following decade, several authors showed the efficacy of IN glucagon (drops, powders, and sprays) to resolve hypoglycemia in normal volunteers and in patients with diabetes, both adults and children.
|
31349701 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of the GLP-1 analogue liraglutide on time in hypoglycaemia, time in hyperglycaemia, and time in range for type 2 diabetes patients initially treated with multiple daily insulin injections (MDI) were investigated.
|
31564026 |
2019 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To understand the relationship of hypoglycemia with meal-related glucose excursion and insulin secretion, we analyzed plasma glucose, insulin, C-peptide, glucagon and incretins obtained during standardized mixed-meal tolerance tests (MMTT) in non-diabetic adolescents and young adults with pancreatic insufficient CF (PI-CF).
|
31402215 |
2019 |